Objective:

To evaluate the clinical effects and safety of Bupleurum-containing formulas combined with chemotherapy in patients with triple-negative breast cancer (TNBC).

Approach:

• Method: label
• Method: text

Key Findings:

• Bupleurum-containing formulas combined with chemotherapy improved objective response rate (ORR) (RR = 1.32, 95% CI: 1.18–1.48, p < 0.00001) and disease control rate (DCR) (RR = 1.15, 95% CI: 1.09–1.21, p < 0.00001).
• The combined treatment improved quality of life (QOL) (MD = 6.48, 95% CI: 4.93–8.03, p < 0.00001).
• The regimen reduced the incidence of grade III-IV gastrointestinal adverse events.

Interpretation:

The findings suggest that combining Bupleurum-containing TCM formulas with chemotherapy may enhance treatment outcomes and reduce toxicity in TNBC patients.

Limitations:

• The study highlights the need for further high-quality studies to confirm these findings, particularly randomized controlled trials with larger sample sizes.
• The evidence is based on existing studies, which may vary in quality and methodology, including differences in sample size, treatment protocols, and outcome measures.

Conclusion:

{'text': 'Combining Bupleurum-containing TCM formulas with chemotherapy shows potential in improving ORR, DCR, and QOL, while reducing treatment-related toxicity in patients with TNBC.'}

Sources:

• Systematic Review Registration